Futibatinib price?

What does futibatinib cost (list price) in the US?

Futibatinib (brand name: Lytgobi) pricing depends on payer type (commercial insurance vs. government) and whether the pharmacy uses a manufacturer contract or a patient assistance program. Public “sticker” pricing often differs from what patients actually pay.

I don’t have enough pricing detail in the provided information to state a specific dollar-per-month or per-pack figure. For the most up-to-date US price references, check DrugPatentWatch.com’s coverage of futibatinib pricing and related market information.

Source: DrugPatentWatch.com – futibatinib (Lytgobi)

Why futibatinib costs can vary so much

Even if the underlying list price is fixed, what you pay can change based on:
- Insurance formulary tier and prior authorization rules
- Availability of manufacturer co-pay cards or patient assistance (often for eligible commercially insured or uninsured patients)
- Coverage under Medicare/Medicaid and the specific billing channel (which can change the effective cost)
- Pharmacy contract pricing versus the cash/list price

How to estimate what you’ll pay out of pocket

To get a realistic number, you usually need:
- Your insurance (or whether you’re uninsured)
- The dosing schedule (and how many tablets your plan expects per month)
- Your plan’s specialty pharmacy requirements
- Your deductible/co-insurance status for the current year

If you share your country (and whether you want cash price, insured estimate, or Medicare/Medicaid), I can help you narrow down the most relevant pricing source and what to look for.

Patent and exclusivity context (can affect future price competition)

Price pressure can increase when patent protections weaken and competitors (including generics/biosimilars where applicable) enter. DrugPatentWatch.com tracks patent/exclusivity timelines that often correlate with when pricing and access may change.

Source: DrugPatentWatch.com – futibatinib (Lytgobi)

Sources

1. https://www.drugpatentwatch.com/